Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2021-03-30 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including grant dates, exercise prices, and valuation methods. This type of disclosure regarding capital structure changes and employee compensation via stock options falls under the category of Regulatory Filings (RNS) as it is a specific corporate disclosure required by the exchange that does not fit into more specific categories like Director's Dealing or Share Issue.
2021-03-30 Korean
투자판단관련주요경영사항(이중항체 면역항암제 ABL111의 미국 FDA 제1상 임상시험계획 (IND) 승인)
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from ABL Bio regarding the approval of an Investigational New Drug (IND) application by the US FDA for their drug candidate ABL111. It is a formal disclosure of a material management event (major business matter) filed with the Korean Exchange (KRX). Since it does not fit into specific categories like financial reports, dividends, or M&A, and serves as a general regulatory announcement of a significant corporate development, it is classified as a Regulatory Filing (RNS).
2021-03-29 Korean
사업보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive financial report titled '재무제표에 대한 감사보고서' (Audit Report on Financial Statements) for ABL Bio. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. It covers the fiscal year ending December 31, 2020. Since it is a standalone audit report containing the full financial statements and audit opinion, it is classified as an Audit Report (AR). FY 2020
2021-03-16 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for ABL Bio. It contains the agenda for the 5th Annual General Meeting, including reports on financial statements, board activities, and governance. While it contains some financial information, it is primarily a formal notice and proxy-related material sent to shareholders to inform them of the meeting, voting procedures, and agenda items. This aligns with the definition of a Proxy Solicitation & Information Statement.
2021-03-16 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains the meeting agenda, voting procedures, and financial statements (as required for shareholder review). This falls under the category of Proxy Solicitation & Information Statement.
2021-03-16 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from ABL Bio. It provides the audit opinion, key financial data, and auditor information as required by the Korea Exchange (KRX). While it contains financial data, it is a specific regulatory disclosure regarding the submission of the audit report rather than the full annual report (10-K) or a standalone audit report (AR). Given the structure and the nature of the disclosure, it fits the 'Audit Report / Information' category as it reports the results of the audit process. FY 2020
2021-03-15 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.